Pamrevlumab for Idiopathic Pulmonary Fibrosis
This randomized clinical trial compares the efficacy and safety of pamrevlumab vs placebo for patients with idiopathic pulmonary fibrosis.
Source: jamanetwork.com
Exploratory Outcomes News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Exploratory Outcomes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Exploratory Outcomes Today - Breaking & Trending Today
Biogen Inc.: New Data at ECTRIMS 2021 Highlight Biogen's Focus on Patient-Centered Outcomes and Improving the MS Patient Experience
Full analysis of Phase 3b NOVA study provides insights on efficacy of every six-week dosing with natalizumab as compared to the approved every four-week dosingReal-world analysis shows significantly lower
Source: finanznachrichten.de